THX Pharma Welcomes Sophie Jacq Lapointe to its Board of Directors

THX Pharma, a biopharmaceutical company specializing in the treatment of rare neurological diseases, has announced the appointment of Sophie Jacq Lapointe to its Board of Directors. With over twenty years of experience in the pharmaceutical sector, Ms. Jacq Lapointe brings valuable expertise gained at companies such as Roche, Sanofi, and Ipsen.

This appointment aligns with THX Pharma's strategy to accelerate the registration and commercialization of its treatments internationally. Sophie Jacq Lapointe played a key role in successful launches such as that of Dupixent® at Sanofi Genzyme.

THX Pharma CEO Mathieu Charvériat expressed his enthusiasm for the collaboration, emphasizing its importance to the company's international ambitions. Sophie Jacq Lapointe, for her part, stated that she was delighted to join the company at this crucial stage of its development.